ADMA ADMA Biologics

NASDAQ
$13.21

ADMA Biologics (ADMA) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.0% since its last earnings release on November 4, 2026.

ADMA Biologics Beat Consensus Estimates, Lowers Guidance In-line with Estimates
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.22
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.21

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ADMA Biologics

ADMA Biologics Inc along with its wholly owned subsidiary is a late stage biopharmaceutical company that develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.